AstraZeneca

Article Abstract:

There have been rumors of possible mergers in the pharmaceuticals industry, some of which have involved AstraZeneca. Zeneca and Astra are undergoing an integration process following their merger, which makes it less likely that they will be involved in consolidation than some other companies. The company faces problems such as the end of its patents for Zestril and Losec, and there is likely to be competition from generic products. The company needs to invest in research in order to strengthen its pipleine of new products.

Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1999
AstraZeneca PLC

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Medarex

Article Abstract:

Medarex has the capacity to make humanized antibodies and can use genomic research. The company has set up a number of alliances with major players in the pharmaceutical industry.

Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2001

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Medarex

Article Abstract:

Medarex represents risk for investors, but the company could offer opportunities and has collaboration agreements with a number of companies.

Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2001
Biochemistry, Research and Development in the Physical, Engineering, and Life Sciences, Biotechnology industry, Biotechnology industries

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Management, Pharmaceutical industry, Drugs, Medarex Inc., MEDX
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.